• Almirall's net income rose 36% year over year to EUR 53.3 million in 9M 2026.
• Net sales climbed 8% to EUR 889.2 million, driven mainly by European dermatology growth led by Ilumetri and Ebglyss.
• Ebglyss net sales jumped 75% to EUR 132.1 million, with continued uptake across launched markets.
• Management reiterated 2026 guidance; four proof-of-concept/Phase II studies remained ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.